

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla, et al.

For: 2' and 3'-Nucleoside Prodrugs for Treating  
Flaviviridae Infections

**POWER OF ATTORNEY BY ASSIGNEE  
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71  
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of U.S. Provisional Patent Application No. 60/392,351, filed June 28, 2002, U.S. Patent Application No. 10/609,298, filed June 27, 2003; and the continuation U.S. Application Nos. 11/005,471; 11/005,442; 11/005,466; 11/005,440; 11/005,443; 11/005,446; 11/005,472; and 11/005,444, filed December 6, 2004, each entitled "2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections," hereby appoints Practitioners of Jones Day associated with Customer Number 20583, which mailing address is Jones Day, 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute these applications and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please direct all correspondence for this application to Customer no. 20583.

**Statement Under 37 C.F.R. 3.73(b)**

UNIVERSITA DEGLI STUDI DI CAGLIARI states that it is:

- ☐ the assignee of the entire right, title, and interest; or  
☒ an assignee of less than the entire right, title and interest.

in the patent applications/patent identified above by virtue of either:

- ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office on \_\_\_\_\_ at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office on \_\_\_\_\_ at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office on \_\_\_\_\_ at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office on  
at Reel , Frame , or for which a copy thereof is attached.


- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached.  
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

**ASSIGNEE: UNIVERSITA DEGLI STUDI DI CAGLIARI**

Date: 13 LUG. 2007

Signature:



Typed Name:

PROF. ADOLFO LAI

Position/Title:

PRO RETTORE

Certifico io Ufficiale Rogante Sostituto  
dell'Università degli Studi di Cagliari  
che la firma, apposta in mia presenza dal  
Prof. Adolfo Lai nato a Ottana il  
28.07.1948, Pro Rettore dell'Università  
di Cagliari e della cui identità personale  
sono certo, è autentica

L'Ufficiale Rogante Sostituto  
Dr. Achille Filiberto Putzu



## ASSIGNMENT

WHEREAS, JEAN-PIERRE SOMMADOSSI, PAOLO LA COLLA and GILLES GOSSELIN, have invented certain improvements in "2' and 3' -Nucleoside Prodrugs for Treating *Flaviviridae* Infections" for which they have executed and filed U.S. non-provisional patent application Serial No. 10/609,298, filed June 27, 2003, and the continuation patent applications thereto identified in Schedule A attached hereto (hereinafter collectively referred to as the "APPLICATIONS FOR LETTERS PATENT");

WHEREAS, PAOLO LA COLLA desires to sell his entire right, title and interest in and to said APPLICATIONS FOR LETTERS PATENT and the inventions set forth therein;


WHEREAS, UNIVERSITA DEGLI STUDI DI CAGLIARI, with a mailing address of Cittadella Universitaria SS 554, Km. 4.500, 09042 MONSERRATO (CA), Italy desires to purchase the same;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by UNIVERSITA DEGLI STUDI DI CAGLIARI, the receipt and sufficiency of which are hereby acknowledged, I, PAOLO LA COLLA, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto UNIVERSITA DEGLI STUDI DI CAGLIARI, in and for the United States and its territories and for foreign countries, my entire right, title and interest in and to said APPLICATIONS FOR LETTERS PATENT, in and to the inventions therein set forth and in and to any patent which may issue on any of said APPLICATIONS FOR LETTERS PATENT or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to any of said APPLICATIONS FOR LETTERS PATENT, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and

assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this \_\_\_\_ day of \_\_\_\_\_, 2006.

  
\_\_\_\_\_  
PAOLO LA COLLA

  
\_\_\_\_\_  
Witness

Date: 26/02/07

SCHEDULE A

Title	Country	Filing Date	Serial No.	Docket Ref.
2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus	US	12/6/04	11/005,442	IDX 1017 CON2
2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus	US	12/6/04	11/005,466	IDX 1017 CON3
2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus	US	12/6/04	11/005,440	IDX 1017 CON4
2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus	US	12/6/04	11/005,443	IDX 1017 CON5
2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus	US	12/6/04	11/005,446	IDX 1017 CON6
2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus	US	12/6/04	11/005,472	IDX 1017 CON7
2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus	US	12/6/04	11/005,444	IDX 1017 CON8

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla, et al.

For: 2' and 3'-Nucleoside Prodrugs for Treating  
Flaviviridae Infections

**POWER OF ATTORNEY BY ASSIGNEE  
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71  
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of U.S. Provisional Patent Application No. 60/392,351, filed June 28, 2002, U.S. Patent Application No. 10/609,298, filed June 27, 2003; and the continuation U.S. Application Nos. 11/005,471; 11/005,442; 11/005,466; 11/005,440; 11/005,443; 11/005,446; 11/005,472; and 11/005,444, filed December 6, 2004, each entitled "2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections," hereby appoints Practitioners of Jones Day associated with Customer Number 20583, which mailing address is Jones Day, 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute these applications and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please direct all correspondence for this application to Customer no. 20583.

**Statement Under 37 C.F.R. 3.73(b)**

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE states that it is:

- ☐ the assignee of the entire right, title, and interest; or  
☒ an assignee of less than the entire right, title and interest.

in the patent applications/patent identified above by virtue of either:

- ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office on \_\_\_\_\_ at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office on \_\_\_\_\_ at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office on \_\_\_\_\_ at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: To:

The document was recorded in the United States Patent and Trademark Office on  
at Reel , Frame , or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached.  
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

**ASSIGNEE: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE**

Date: 14 JUIN 2007 Signature: \_\_\_\_\_  
Typed Name: \_\_\_\_\_  
Position/Title: \_\_\_\_\_

Directeur de la Politique Industrielle

Marc J. LEDOUX

Directeur du Service du Transfert de  
Technologies

Frédéric POUBERT



### ASSIGNMENT

WHEREAS, WE, WHEREAS, WE, JEAN-PIERRE SOMMADOSSI, GILLES GOSSELIN, PAOLO LA COLLA, ADEL M. MOUSSA, RICHARD STORER, CLAIRE PIERRA, SAMIRA BENZARIA, AND DAVID DUKHAN have invented certain improvements in "2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus" for which We have executed a United States Provisional Application No. 60/392,351 on June 28, 2002 and

WHEREAS, Centre National Da La Recherche Scientifique (CNRS), a public agency operating under the supervisory authority of France's Ministry of Research and Technology, located at 3, Rue Michel-ange 75794, Paris, cedex 16, France desires to purchase same;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by Centre National Da La Recherche Scientifique (CNRS), the receipt and sufficiency of which are hereby acknowledged, I, GILLES GOSSELIN, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto Centre National Da La Recherche Scientifique (CNRS), in and for the United States and its territories, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.



IN WITNESS WHEREOF, I have hereunto set my hand and seal this 13 day of  
December, 2002.



GILLES GOSSELIN

On this 13 day of December, 2002, before me, a notary public, came  
Gilles Gosse, to me known and known to be the individual described in and  
who executed the foregoing assignment, and he acknowledged the same to be his free act  
and deed.



  
Notary Public

(SEAL)

My commission expires; \_\_\_\_\_

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla, et al.

For: 2' and 3'-Nucleoside Prodrugs for Treating  
Flaviviridae Infections

**POWER OF ATTORNEY BY ASSIGNEE  
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71  
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of U.S. Provisional Patent Application No. 60/392,351, filed June 28, 2002, U.S. Patent Application No. 10/609,298, filed June 27, 2003; and the continuation U.S. Application Nos. 11/005,471; 11/005,442; 11/005,466; 11/005,440; 11/005,443; 11/005,446; 11/005,472; and 11/005,444, filed December 6, 2004, each entitled "2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections," hereby appoints Practitioners of Jones Day associated with Customer Number 20583, which mailing address is Jones Day, 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute these applications and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please direct all correspondence for this application to Customer no. 20583.

**Statement Under 37 C.F.R. 3.73(b)**

IDENIX PHARMACEUTICALS, INC. states that it is:

- ☐ the assignee of the entire right, title, and interest; or  
☒ an assignee of less than the entire right, title and interest.

in the patent applications/patent identified above by virtue of either:

- ☒ An assignment from the inventor(s) of the patent application/patent identified above.  
The assignment was recorded in the United States Patent and Trademark Office on  
at Reel , Frame , or for which a copy thereof is attached.

OR

- ☐ A chain of title from the inventor(s), of the patent application/patent identified above,  
to the current assignee as shown below:

1. From: To:  
The document was recorded in the United States Patent and Trademark Office on  
at Reel , Frame , or for which a copy thereof is attached.
2. From: To:  
The document was recorded in the United States Patent and Trademark Office on  
at Reel , Frame , or for which a copy thereof is attached.
3. From: To:

The document was recorded in the United States Patent and Trademark Office on  
at Reel , Frame , or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached.  
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: IDENIX PHARMACEUTICALS, INC.

Date:

June 1, 2007

Signature:



Typed Name:

Position/Title:

JEAN-PIERRE SOMMADOSSI, Ph.D.  
CHAIRMAN AND CEO  
IDENIX PHARMACEUTICALS, INC.

ASSIGNMENT

WHEREAS, WE, WHEREAS, WE, JEAN-PIERRE SOMMADOSSI, GILLES GOSSELIN, PAOLO LA COLLA, ADEL M. MOUSSA, RICHARD STORER, CLAIRE PIERRA, SAMIRA BENZARIA, AND DAVID DUKHAN have invented certain improvements in "2' and 3'- Nucleoside Prodrugs for Treating Hepatitis C Virus" for which We have executed a United States Provisional Application No. 60/392,351 on June 28, 2002 and

WHEREAS, IDENIX PHARMACEUTICALS INC., a Delaware corporation having an office at 125 Cambridgepark Drive, Cambridge, MA 02140 desires to purchase same;


NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by IDENIX PHARMACEUTICALS INC., the receipt and sufficiency of which are hereby acknowledged, I, JEAN-PIERRE SOMMADOSSI, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto IDENIX PHARMACEUTICALS INC., in and for the United States and its territories, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 19<sup>th</sup> day of

December, 2002.

  
JEAN-PIERRE THOMADOSSI

On this 19<sup>th</sup> day of December, 2002, before me, a notary public, came Jean-Pierre Thomadossi to me known and known to be the individual described in and who executed the foregoing assignment, and he duly acknowledged the same to be his free act and deed.

  
Notary Public

(SEAL)

My commission expires: CYNTHIA B. GAGNE  
Notary Public  
My Comm. Expires Sept. 25, 2003